J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522640-41-00

Acronym

J2S-MC-GZMR

Enrollment

Registered

2026-01-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Annualized Asthma Exacerbation Rate Over 52 Weeks of treatment to assess the asthma exacerbation rate. [Time Frame: Baseline to Week 52]

Interventions

DRUGBrenipatide

DRUGPlacebo to match LY

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Annualized Asthma Exacerbation Rate Over 52 Weeks of treatment to assess the asthma exacerbation rate. [Time Frame: Baseline to Week 52]	—

Countries

France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026